RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.
RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.